Arcadia Biosciences (RKDA) Earning Somewhat Favorable News Coverage, Accern Reports

News coverage about Arcadia Biosciences (NASDAQ:RKDA) has trended somewhat positive this week, Accern reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Arcadia Biosciences earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave media stories about the basic materials company an impact score of 46.2234849846569 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of Arcadia Biosciences (NASDAQ RKDA) opened at $0.23 on Wednesday. Arcadia Biosciences has a 12-month low of $0.20 and a 12-month high of $1.50.

WARNING: This article was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://stocknewstimes.com/2017/12/06/arcadia-biosciences-rkda-earning-somewhat-favorable-news-coverage-accern-reports.html.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc is an agricultural biotechnology trait company. The Company develops a portfolio of yield and traits addressing multiple crops that supply the global food and feed markets. It has a pipeline of products in development incorporating its traits, including products that are in advanced stages of development or on the market.

Insider Buying and Selling by Quarter for Arcadia Biosciences (NASDAQ:RKDA)

Receive News & Ratings for Arcadia Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply